Skyrocketing Stocks! Get Rich Off These 2 Companies

These two stocks have given investors incredible returns this year. Best of all? They are still small caps. Should you buy them for your portfolio?

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Stocks that can return 1,000% gains in one year come once in a blue moon. Often, these are companies that are penny stocks and have little to no real substance behind the massive price action. However, this year, two companies listed on the Toronto Stock Exchange have given investors remarkable growth. One of these companies has managed to climb more than 1,000% over the past year. The other is led by a former billionaire hedge fund manager. Should you buy them?

An interesting biotech company

Biotech companies can be tricky for investors to get into. A lot of them work on therapies that most individuals do not have a lot of background in. Therefore doing due diligence on these companies can be tougher than investing in a company like Apple or Amazon. However, there are some companies that are doing work that should be noted.

Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) is a Canadian biotechnology company that focuses on immuno-oncology. The company targets a protein named CD47. Tumours often use this protein to evade the immune system. The company’s website puts this simply, explaining that CD47 emits a “don’t eat me” signal, which blocks macrophages (a type of white blood cell responsible for detecting and destroying pathogens and apoptotic cells).

By disabling this “don’t eat me” signal, Trillium hopes to be able to unmask harmful tumours and help make them visible to the immune system. If successful, this could have massive implications in the oncology space.

In 2019, Trillium underwent massive changes, which included corporate reorganization. It was at this time that the company’s stock fortunes changed for the better. After seeing as much as a 98% decline over the past five years, Trillium stock has climbed more than 5,700% over the past year. Year to date, its stock has climbed nearly 1,000%.

The company still only has a market cap of about $1.9 billion, so there is definitely still a lot of room for growth. However, investors should be warned that investing in biotech companies comes with its risks. As promising as they can be, many of them face tremendous difficulties throughout the therapy development process.

This company is an interesting play on cryptocurrencies

Cryptocurrencies, such as Bitcoin, are very polarizing among investors. Some believe that the upside in these currencies is tremendous, banking on an eventual widespread use of Bitcoin or Ethereum.

However, there are others that think cryptocurrencies are pure speculation since they have no fundamentals that investors can point to to justify price movements. Nevertheless, we have been seeing an increasing number of funds and public companies that focus on this space.

Galaxy Digital (TSX:GLXY) is a diversified financial services and investment management company that focuses in this controversial space. The company aims to make cryptocurrencies and other digital assets a readily available alternative asset class for institutions and high net worth individuals. The company was founded by its CEO, Michael Novogratz. He was previously the president of Fortress Investment Group and worked at Goldman Sachs for over a decade.

The company first listed on the TSX on July 2. Since then, it has seen great stock appreciation. Since that time, Galaxy stock has climbed more than 275%. With a market cap of about $400 million, and a crypto space that is only becoming more popular, an argument can be made that this is still only the very beginning of Galaxy Digital’s growth story.

Just Released! 5 Stocks Under $50 (FREE REPORT)

Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $50 a share.

Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.

Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.

Claim your FREE 5-stock report now!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor Jed Lloren owns shares of Apple. David Gardner owns shares of Amazon and Apple. The Motley Fool owns shares of and recommends Amazon and Apple and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon.

If You Thought Apple and Microsoft Were Big, You Need to Read This.

The steel industry produced the world's first $1 billion company in 1901, and it wasn't until 117 years later that technology giant Apple became the first-ever company to reach a $1 trillion valuation.

But what if I told you artificial intelligence (AI) is about to accelerate the pace of value creation? AI has the potential to produce several trillion-dollar companies in the future, and The Motley Fool is watching one very closely right now.

Don't fumble this potential wealth-building opportunity by navigating it alone. The Motley Fool has a proven track record of picking revolutionary growth stocks early, from Netflix to Amazon, so become a premium member today.

See the 'AI Supercycle' Stock

More on Investing

dividends can compound over time
Investing

1 Undervalued TSX Stock Down 42% to Buy and Hold

Down 42% from recent highs, GDI is an undervalued TSX stock that trades at a discount to consensus price targets.

Read more »

Piggy bank in autumn leaves
Bank Stocks

Better Banking Stock: Bank of Montreal vs Bank of Nova Scotia

Bank of Montreal and Bank of Nova Scotia are up considerably in the past six months. Is one headed higher…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Investing

Trump’s Trade War: 3 Immediate Moves to Protect Your Wealth

RioCan Real Estate Investment Trust (TSX:REI.UN) is not strongly impacted by Trump tariffs.

Read more »

Investor wonders if it's safe to buy stocks now
Investing

Canadian Tire: Buy, Sell, or Hold in 2025?

Let's dive into where Canadian Tire (TSX:CTC.A) could be headed in 2025, and if this is a stock worth considering…

Read more »

Middle aged man drinks coffee
Dividend Stocks

Should You Buy Goeasy Stock While It’s Below $170?

Goeasy stock still looks like a winner, so why is the stock price down below $170?

Read more »

nugget gold
Metals and Mining Stocks

Kinross Gold: Buy, Sell, or Hold in 2025?

Kinross Gold (TSX:K) stock: Buy the dip as gold nears $3k? 2025 investment opportunities outlook and analysis

Read more »

Piggy bank with word TFSA for tax-free savings accounts.
Dividend Stocks

Maximizing Your TFSA: Smart Investment Moves for 2025

Stocks like Enbridge provide significant dividend income, which is ideal for tax-savings within your TFSA.

Read more »

analyze data
Dividend Stocks

Outlook for Brookfield Infrastructure Partners Stock in 2025

Brookfield Infrastructure Partners (TSX:BIP.UN) has been doing a lot of growing lately.

Read more »